Georgious Tsoulfas
University of Rochester Medical Center
4 Papers
37 Citations
Georgious Tsoulfas is an academic researcher from University of Rochester Medical Center. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 3, co-authored 3 publications. Previous affiliations of Georgious Tsoulfas include University of Rochester.
Chat about Author
Papers
Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients.
Ashok Jain,Raman Venkataramanan,Rajeev Sharma,Tai Kwong,Mark S. Orloff,Peter L. Abt,Randeep Kashyap,Georgious Tsoulfas,Pam Batzold,Mary A. Williamson,Adel Bozorgzadeh +10 more
TL;DR: An initial tacrolimus dose reduction of about 30–40% may be prudent in LDLT compared with DDLT recipients, and although not statistically significant, the dose normalized AUC was 37.7% greater and clearance 47.5% lower in HDLT as compared withDDLT.
Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction
Ashokkumar Jain,Rajeev Sharma,Charlotte K. Ryan,Georgious Tsoulfas,Mark S. Orloff,Peter L. Abt,Randeep Kashyap,Pam Batzold,Lisa Sauberman,Saman Safadjou,Maureen Graham,Adel Bozorgzadeh +11 more
TL;DR: IV MMF with tacrolimus and steroids is useful and required antirejection therapy in 6.1% of liver transplant recipients, and all patients responded to steroid therapy.
16
Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients.
Ashokkumar Jain,Raman Venkataramanan,Rajeev Sharma,Tai Kwong,Peter L. Abt,Mark S. Orloff,Randeep Kashyap,Georgious Tsoulfas,Adel Bozorgzadeh +8 more
TL;DR: Observations point to the need to use a lower dosage (approximately 30%) of mycophenolate mofetil in live donor liver transplant patients compared with deceased donor liver transplants patients.
9
Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease.
Emmanouil Sinakos,Pam Panas,Nikolaos Fragkou,Nikolaos Antoniadis,Georgios Katsanos,E Tsakni,Theodora Oikonomou,A Notopoulos,Georgious Tsoulfas,Ioannis Goulis,Evangelos Akriviadis +10 more
- 01 Jun 2022
TL;DR: Conversion to TAF in post-LT patients who develop CKD does not lead to improvement of kidney function after a period of one year, and the use of everolimus was associated with improvement in renal function.
3